UK markets open in 4 hours 30 minutes

Scancell Holdings plc (SCLP.L)

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
23.25+0.75 (+3.33%)
At close: 05:05PM GMT

Scancell Holdings plc

Bellhouse Building
Unit 202 Sanders Road Oxford Science Park
Oxford OX4 4GD
United Kingdom
44 18 6558 2066

Full-time employees40

Key executives

NameTitlePayExercisedYear born
Prof. Lindy Gillian Durrant Ph.D.Founder, CEO, Chief Scientific Officer & Director376.88kN/AN/A
Dr. Sally Elizabeth AdamsChief Devel. Officer & Director255.65kN/A1961
Mr. Keith GreenDirector of Fin. & Admin. and Company Sec.N/AN/AN/A
Dr. Samantha Paston Ph.D.Head of Translational ResearchN/AN/AN/A
Dr. Adrian Parry Ph.D.Head of ManufacturingN/AN/AN/A
Ms. Akua AsareHead of QualityN/AN/AN/A
Mr. Fayaz MasterHead of Clinical OperationsN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.


Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel vaccines and antibody medicines to treat unmet needs in cancer and infectious diseases. The company's product candidates include SCIB1, an ImmunoBody cancer vaccine for the treatment of metastatic melanoma; SCIB2/iSCIB2 vaccine, which is under evaluation for the treatment of patients with solid tumours, including non-small cell lung cancer; and Modi-1 that is in phase I/II clinical trials for the treatment of head and neck, triple negative breast, ovarian, and renal cancers. It also develops Modi-2, which targets homocitrullinated cancer antigens. In addition, the company develops SCOV1 and SCOV2 COVIDITY, a DNA vaccine against the SARS-CoV-2 virus. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.

Corporate governance

Scancell Holdings plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.